Hairy Cell Leukemia - Pipeline Review, H2 2017

  • ID: 4419037
  • Report
  • 92 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ARA Healthcare Pvt Ltd
  • Astellas Pharma Inc
  • Cellectis SA
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd
  • MORE
Hairy Cell Leukemia - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2017, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ARA Healthcare Pvt Ltd
  • Astellas Pharma Inc
  • Cellectis SA
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd
  • MORE
Introduction

Hairy Cell Leukemia - Overview

Hairy Cell Leukemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hairy Cell Leukemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hairy Cell Leukemia - Companies Involved in Therapeutics Development

AbbVie Inc

ARA Healthcare Pvt Ltd

Astellas Pharma Inc

Cellectis SA

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Incyte Corp

MedImmune LLC

Novartis AG

Hairy Cell Leukemia - Drug Profiles

AGS-67E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARABS-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezapelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit CD25 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-50465 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

moxetumomab pasudotox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCART-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vemurafenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hairy Cell Leukemia - Dormant Projects

Hairy Cell Leukemia - Discontinued Products

Hairy Cell Leukemia - Product Development Milestones

Featured News & Press Releases

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumors

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hairy Cell Leukemia, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Hairy Cell Leukemia - Pipeline by AbbVie Inc, H2

Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt Ltd, H2

Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc, H2

Hairy Cell Leukemia - Pipeline by Cellectis SA, H2

Hairy Cell Leukemia - Pipeline by Elsalys Biotech SAS, H2

Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2

Hairy Cell Leukemia - Pipeline by Incyte Corp, H2

Hairy Cell Leukemia - Pipeline by MedImmune LLC, H2

Hairy Cell Leukemia - Pipeline by Novartis AG, H2

Hairy Cell Leukemia - Dormant Projects, H2

Hairy Cell Leukemia - Discontinued Products, H2

List of Figures

Number of Products under Development for Hairy Cell Leukemia, H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • ARA Healthcare Pvt Ltd
  • Astellas Pharma Inc
  • Cellectis SA
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • MedImmune LLC
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll